Cargando…
OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer
BACKGROUND: Metastatic prostate cancer remains a common cause of death in Europe, and improvements in management of the disease are urgently needed. The advent of positron-emission tomography (PET) imaging enhanced with fluorocholine has led to the identification of a new sub-group of metastatic pro...
Autores principales: | Supiot, Stephane, Rio, Emmanuel, Pacteau, Valérie, Mauboussin, Marie-Hélène, Campion, Loïc, Pein, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582833/ https://www.ncbi.nlm.nih.gov/pubmed/26408012 http://dx.doi.org/10.1186/s12885-015-1579-0 |
Ejemplares similares
-
Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP
por: Supiot, Stéphane, et al.
Publicado: (2018) -
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol
por: Rogé, Maximilien, et al.
Publicado: (2023) -
Invited commentary on GETUG-AFU 16
por: Lee, W. Robert
Publicado: (2016) -
The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer
por: Bogdanova, Natalia V., et al.
Publicado: (2022) -
GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy—study protocol
por: Pasquier, David, et al.
Publicado: (2019)